



TEXAS IS LEADING THE FIGHT AGAINST CHILDHOOD AND ADOLESCENT CANCER

By prioritizing childhood and adolescent cancer through recruiting world class childhood and adolescent cancer researchers to Texas, supporting collaborative research at Texas' leading institutions and early-stage companies, and focusing efforts on preventing cancer now and in the future, the state is leading the way to a healthier future for Texas' children and their families.

THE CHALLENGE


The types of cancers that develop in children are often different from adult cancers and most treatments frequently cause significant lifelong side effects for childhood cancer survivors.



Texas children and adolescents diagnosed with cancer in 2024



Texas children and adolescents will die from cancer in 2024



Increase in childhood cancer rates in U.S. since 1975

THE COMMITMENT

CPRIT's Oversight Committee, with the advice and input from our Advisory Committee on Childhood Cancers, established the discovery of improved treatments and cures for childhood and adolescent cancers as a statewide research priority in 2014.

\$440,255,642

CPRIT investment in childhood and adolescent cancer research -proportionally 3 times more than the national commitment

238

CPRIT-funded childhood cancer projects

47 - 12,173

CPRIT-funded childhood cancer clinical trials or studies and number of childhood cancer patients impacted

\$20,000,000+

CPRIT funding for research on Ewing's Sarcoma, a rare bone cancer afflicting children and adolescents

“ CPRIT has been a powerful engine for driving childhood, adolescent and young adult cancer research in Texas, positioning the state as a national leader in the field while positively impacting patients and their families. ”

Richard Gorlick, M.D

*Chair
CPRIT Advisory Committee on Childhood Cancers*



CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS

cprit.texas.gov



Last Updated May 2024



Preventing future cancers through HPV vaccinations

CPRIT awarded a \$1 million grant to **Dr. Allison Grimes** with the Greehey Children's Cancer Research Institute at UT Health San Antonio in an effort to prevent HPV-related cancers in childhood cancer survivors. Human papillomavirus (HPV) contributes to more than 30,000 new cancers in the U.S. every year, with childhood cancer survivors at particular risk. This program partners with 10 pediatric oncology centers and five geographically and institutionally diverse expansion sites across Texas.

Grant #: PP230061



Nanosized immunotherapies to access and treat pediatric medulloblastoma

CPRIT awarded a \$200,000 grant to The University of Texas at Austin researcher **Dr. Jennifer Maynard** in 2019 to develop nanosized immunotherapies to improve treatments for medulloblastoma, a deadly tumor that accounts for almost 20% of pediatric brain tumors and occurs most frequently in children between the ages of 3 and 8. Current therapies rely on radiation, which provides only a brief respite from disease but can cause significant damage to healthy brain tissue. Dr. Maynard's research aims to generate a multi-functional antibody able to penetrate the blood-brain barrier and starve the cancer cells.


Grant #: RP190653



The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas

CPRIT awarded a \$4 million Core Facility Support Award to Baylor College of Medicine's **Michael Scheurer** in 2021 for "The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service" (ACCESS) for Texas project. ACCESS-Texas is a biorepository and data bank that provides researchers throughout the state with rich data and specimens for the discovery of novel biomarkers for cancer predisposition, early detection, and diagnosis for childhood and adolescent cancers. ACCESS-Texas positions Texas researchers to develop and lead international collaborations to explore novel risk factors for childhood cancers.

Grant #: RP210064



Targeting Acute Lymphoblastic Leukemia

CPRIT awarded an \$11.7 million grant to Houston-based **Allterum Therapeutics**, an early-stage bioscience company developing a novel drug to treat acute lymphoblastic leukemia (ALL), the most common childhood cancer. Allterum's targeted monoclonal antibody is designed to kill ALL cancer cells without the broader, more severe, side-effects typically observed with conventional chemotherapies.

Grant #: DP230071



Advancing treatments for neuroblastoma at Texas Tech University Health Sciences Center

CPRIT awarded a \$1.2 million grant to **Dr. Charles Reynolds** at Texas Tech Health Sciences Center that may lead to new treatments for neuroblastoma, a lethal malignancy of the nervous system that accounts for 8% of childhood cancers. Dr. Reynolds' work could be a game changer for children whose high-risk neuroblastoma has become chemotherapy resistant.

Grant #: RP200432



Recruiting new leukemia fighters to Texas institutions

CPRIT recruited epigeneticist **Margarida I. Albuquerque Almeida Santos** from the National Cancer Institute to The University of Texas M.D. Anderson Cancer Center with a First-Time, Tenure Track Faculty Member grant. Dr. Santos' research focuses on a type of acute myeloid leukemia common in children in hopes of developing new treatments.

Grant #: RR150039